A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 22
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DA
Long Form : L-DOPA and dopamine
No. Year Title Co-occurring Abbreviation
2018 Changes in thermoregulation and monoamine release in freely moving rats during cold exposure and inhibition of the ventromedial, dorsomedial, or posterior hypothalamus. ACT, DMH, HR, PH, Tb, TTX, VMH
2017 Copper-mediated DNA damage by the neurotransmitter dopamine and L-DOPA: A pro-oxidant mechanism. ---
2014 Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease. COMT, l-dopa, MPTP, PD
2012 Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. CDD, CDS, PD
2010 The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. i.p
2008 Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. PD
2003 Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. ESR, HMPE, SOD, TUNEL
2003 DOPA cyclohexyl ester potently inhibits aglycemia-induced release of glutamate in rat striatal slices. alpha-MPT, AMPA, DOPA, DOPA CHE, TTX
2001 Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma. DOPA, DOPAC, HVA, MAO, NB, VMA
10  2000 Drug treatment of Parkinson's disease. Time for phase II. NQO, PD
11  2000 Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease. DOPAC, HVA, i.p, L-DOPA, NAC
12  1997 Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients. 3-OMD, 5-HT, NE, PD, VP
13  1997 [Evaluation of the usefulness for measuring catecholamines and their principle metabolites in the diagnosis of pheochromocytoma]. NA, VMA
14  1996 Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. CNQX
15  1995 Effects of chronic activation of dopamine D-2 receptors in cultures of rat fetal dopaminergic neurons: indications for alterations in functional activity. TH
16  1992 L-dopa administration enhances exocytotic dopamine release in vivo in the rat striatum. L-DOPA
17  1991 [Dopamine antibodies in the pathogenesis of parkinsonism]. ---
18  1989 [The DOPA and dopamine content in the hypothalamus and brain stem of rats with an experimental stomach ulcer against a background of a course of acupuncture]. AP, EUS
19  1988 Determinations of catechols in small volumes of plasma using ion-pair reversed phase liquid chromatography/electrochemistry. CA, CP-O, NA
20  1987 Study on adrenergic function after development of tolerance to ethylene glycol dinitrate (EGDN) in rats. CA, EGDN, HR, MAP, NA
21  1980 Hypothalamic catecholamine biosynthesis in vitro as measured by liquid chromatography and electrochemical detection. alpha mpt, LCEC, NE
22  1979 gamma-Glutamyl DOPA and gamma-glutamyl dopamine: effect on plasma glucose levels. gamma-glutamyl DA, gamma-glutamyl DOPA